

Attorney Docket No.: PENN-0065
Inventors: Wolfe and Fraser
Serial No.: 08/393,066
Filing Date: February 23, 1995
Page 2

In the Claims:

Spec 1 → 1. (amended) A method of delivering a selected DNA sequence to the central nervous system of a mammal comprising administering a neurotropic viral vector [capable of infecting] which infects the central nervous system of a mammal, said vector containing a selected DNA sequence, said sequence being operatively linked to a selected promoter.

REMARKS

Claims 1-9 are pending in this application. Claims 1-9 have been rejected. Claim 1 has been amended. Reconsideration is respectfully requested in light of this amendment and the following remarks.

I. Objection to Specification and Rejection of Claims 1-9 under 35 U.S.C. §112, first paragraph

The objection to the specification and rejection of claims 1-9 under 35 U.S.C. §112, first paragraph, have been maintained, as the Examiner suggests that it is not apparent from the disclosure that the method would sufficiently deliver a gene to the central nervous system. As acknowledged by the Examiner, Applicants have shown that biologically active β -glucuronidase can be expressed when the DNA sequence for an HSV vector is administered by corneal abrasion.